Amarin (AMRN)
(Delayed Data from NSDQ)
$0.69 USD
-0.02 (-2.64%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $0.68 -0.01 (-0.93%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Price, Consensus and EPS Surprise
AMRN 0.69 -0.02(-2.64%)
Will AMRN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMRN
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
AMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Other News for AMRN
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Amarin falls on CEO exit and Vascepa coverage update